It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.
For a biotech, your intellectual property is your most prized asset. But a new era of increased global competition means that strong patents, longer stealth periods and even some misdirection can be required to ensure drug developers retain an edge.
Clinical integration is not achieved through governance structures alone. It depends on whether the organization has developed the operational capabilities required to execute consistently across markets that historically functioned independently. The post What Health Systems Miss When Building National Service Lines appeared first on MedCity News .
Runners participating in Japanese marathon races largely held in autumn and winter had a greater risk of sudden cardiac arrest (SCA) when the ambient temperature was lower at race start, while no significant relationship between ambient air pollutants and SCA risk was identified, according to a study published June 30 in JACC: Advances.
The market for robotic surgery got more competitive this year, with Medtronic, Stryker, CMR Surgical and Distalmotion introducing new platforms. Check up on their progress and more in MedTech Dive’s roundup of robotics coverage.
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unnamed pharma company in April.
Insurance coverage losses caused by the Trump administration's tax and spend law could make it harder for biotechs to secure funding and recruit patients for trials, experts have told Fierce.